ERBB2 and breast cancer: In addition, BC patients with triple-negative (HR(−)/HER2(−)) BC have more aggressive BC and a higher risk of sdMTS appearance than BC patients positive for the progesterone receptor PR(+) who have a lower risk of sdMTS appearance.